Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Lusutrombopag for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Able to understand the study and comply with all study procedures.~2. Willing to provide written informed consent prior to Screening.~3. Male or female.~4. 18 years of age or older at the time of signing informed consent.~5. Platelet count \< 50 × 10\^9/L at baseline on Day 1 prior to randomization.~6. Undergoing an elective invasive procedure.~7. In the opinion of the investigator, able to meet study requirements.~8. Male patients who are sterile or who agree to use an appropriate method of contraception (including use of a condom with spermicide) from Screening to completion of the Post-treatment Period.~9. Female patients who are not postmenopausal or surgically sterile need to agree to use a highly effective contraception (including contraceptive implant, injectable contraceptive, combination hormonal contraceptive \[including vaginal rings\], intrauterine contraceptive device or vasectomised partner) from Screening to completion of the Post-treatment Period. Barrier method with or without spermicide, double barrier contraception and oral contraceptive pill are insufficient methods on their own.~Exclusion Criteria:~1. Any of the following diseases:~   * hematopoietic tumor~  * aplastic anemia~  * myelodysplastic syndrome~  * myelofibrosis~  * congenital thrombocytopenia~  * drug-induced thrombocytopenia~  * generalized infection requiring treatment except for viral liver disease~  * immune thrombocytopenia.~2. History of splenectomy.~3. History of liver transplantation.~4. Any of the following at Screening:~   * hepatic encephalopathy uncontrolled by drugs~  * ascites uncontrolled by drugs.~5. Portal vein tumor embolism.~6. Known to be positive for the human immunodeficiency virus.~7. Past or present thrombosis or prothrombotic condition (e.g., cerebral infarction, myocardial infarction, angina pectoris, coronary artery stent placement, angioplasty, coronary artery bypass grafting, congestive heart failure \[New York Heart Association Grade III/IV\], arrhythmia known to increase the risk of thromboembolic events \[atrial fibrillation\], pulmonary thromboembolism, deep vein thrombosis, or disseminated intravascular coagulation syndrome).~8. History or evidence of any of the following diseases:~   * congenital thrombotic disease (eg, antithrombin deficiency, protein C deficiency, protein S deficiency, or coagulation factor \[Factor V Leiden\] mutation)~  * acquired thrombotic disease (eg, antiphospholipid antibody syndrome, paroxysmal nocturnal hemoglobinuria, hyperhomocysteinemia, or increased factor VIII)~  * Budd Chiari syndrome.~9. Portal vein thrombosis based on ultrasound, computed tomography (CT), or magnetic resonance imaging (MRI) within 28 days prior to randomization or a history of portal vein thrombosis.~10. Absence of hepatopetal blood flow in the main trunk of the portal vein as demonstrated by Doppler ultrasonography within 28 days prior to randomization.~11. History or evidence of disease associated with a risk of bleeding (e.g., coagulation factor deficiency or von Willebrand factor deficiency).~12. Bleeding score at randomization ≥ Grade 2 according to the World Health Organization (WHO) Bleeding Scale.~13. Any of the following drugs or therapies within 90 days prior to randomization:~    * anticancer drugs~   * interferon preparations~   * radiation therapy~   * exsanguination~   * other thrombopoietin receptor agonist~   * any investigational agent.~14. Any invasive procedure within 14 days prior to randomization.~15. Blood transfusion within 14 days prior to randomization.~16. Prior treatment with lusutrombopag (S-888711).~17. Pregnancy or lactation.~18. Known or suspected ongoing, active alcohol or substance abuse. Patients with a recent history who the investigator feels are able to comply with the study procedures and medications will be allowed to participate.~19. Considered ineligible by the investigator for any other reason.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lusutrombopag (Type: EXPERIMENTAL): Lusutrombopag 3 mg once daily for up to 7 days.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo once daily for up to 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).